The Research Institute for Biological Safety Problems of the Science Committee of the Ministry of Education and Science of the Republic of Kazakhstan (RIBSP) is recruiting volunteers who will take part in the study of a coronavirus vaccine.
The study will be conducted at the clinical base of the National Scientific Center for Phthisiopulmonology. The age of the volunteers who can take part in the vaccine trial is from 18 to 50 years old, all participants must be in excellent health.
What are the requirements for volunteers:
No history of COVID-19 diagnosis. In addition, in the last 14 days from the start of the study, volunteers should not be in close contact with people who have laboratory-confirmed coronavirus or suspected of being infected. Also, according to the rules of the study, participants should not have chronic infections and any allergic reactions. People with alcohol and drug addiction, mental disorders, serious endocrine and kidney disorders will not be allowed to take part in the tests. Volunteers should not be registered with chronic heart and circulatory system diseases. Pregnant and lactating women will also not be able to participate in the study.
Everyone who is admitted to vaccination must sign a voluntary informed consent, keep a daily self-observation diary and visit a doctor on time for several weeks. Each participant of the study will be provided with insurance.
You can get acquainted with the list of indications and contraindications in more detail after submitting an application. Professor B.M. Khairullin was appointed the main researcher from RIBSP.
Please send preliminary questionnaires to
This questionnaire is intended for the selection of volunteers who are ready to take part in clinical trials of the QazCovid-in® COVID-19 inactivated vaccine.
All information collected using this questionnaire is confidential, protected by the legislation of the Republic of Kazakhstan on the protection of personal data, is not subject to disclosure without your consent, and can only be used for the purpose of conducting clinical trials of the Kazakhstani QazCovid-in® – COVID-19 inactivated vaccine.
Recall that the World Health Organization (WHO) has included the Kazakhstan inactivated coronavirus vaccine in the list of candidate vaccines admitted to clinical trials. The domestic vaccine is now in phase 1/2 of clinical trials.
The Kazakhstan QazCovid-in® – COVID-19 inactivated vaccine is registered by WHO as a candidate vaccine for Phase I and II clinical trials. This was reported on the official website of the WHO. A total of 33 candidate vaccines from 19 countries are in clinical trials